Form 4: Verve Therapeutics Director Burt Adelman Receives Significant Stock Option Grant

Verve Therapeutics, Inc. director Burt A. Adelman was granted 42,200 stock options as part of the company's 2021 Stock Incentive Plan and director compensation program.

Summary

• Burt A. Adelman, a Director of Verve Therapeutics, Inc. (VERV), was granted 42,200 stock options.
• The transaction date for this grant was June 5, 2025.
• The exercise price for these options is $5.73 per share.
• The options were issued under the 2021 Stock Incentive Plan of Verve Therapeutics, Inc., consistent with its director compensation program.
• The vesting commencement date is the grant date (June 5, 2025).
• All shares underlying the option vest upon the earlier of the one-year anniversary of the vesting commencement date or immediately prior to the first annual meeting of stockholders occurring after the grant date.
• Vesting is subject to Mr. Adelman's continued service as a director.
• The options have an expiration date of June 4, 2035.
• Following this transaction, Mr. Adelman beneficially owns 42,200 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The document reports a routine, positive event of a director receiving stock options, which aligns management interests with shareholders. It does not contain any negative or unexpected information, nor does it suggest any immediate significant impact on the company's financial standing beyond standard compensation practices.

Positives

• The grant of stock options to Director Burt A. Adelman aligns his interests with those of the shareholders, incentivizing long-term value creation.
• The transaction is part of a pre-existing and disclosed 2021 Stock Incentive Plan, indicating a structured approach to executive and director compensation.

Future Outlook

The vesting schedule for the options, tied to continued service as a director, indicates an expectation of Burt A. Adelman's ongoing involvement with Verve Therapeutics for at least the next year or until the next annual meeting of stockholders.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of compensation packages designed to attract and retain experienced board members and align their interests with long-term company performance.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The specific size of the grant (42,200 options) and the exercise price ($5.73) would typically be evaluated against peer companies of similar market capitalization and stage of development within the biotech industry, though specific comparables are not provided in this filing.
• The vesting schedule (one-year anniversary or prior to next annual meeting) is also a common structure for director equity awards, promoting retention and alignment.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term shareholder value creation, as the options gain value if the stock price increases.
• Director (Burt A. Adelman): Receives equity compensation, incentivizing continued service and performance.

Next Steps

• The granted stock options will vest based on the specified conditions (earlier of one-year anniversary of grant or prior to the first annual meeting of stockholders after grant date), subject to continued service.
• Upon vesting, the director will have the right to exercise these options to acquire common stock of Verve Therapeutics, Inc.

Key Dates

Keywords

Verve Therapeutics, VERV, Stock Option, Director Compensation, Insider Transaction, Form 4, Equity Grant, Biotechnology, Pharmaceuticals